Viagra May Slow the Spread of Cancer

In a surprising twist, the erectile dysfunction drug Viagra might hold potential in slowing the spread of cancer, according to a recent study published in Cancer Research. Originally developed by Pfizer to treat chest pain and high blood pressure, sildenafil was found to inhibit phosphodiesterase type 5 (PDE5), an enzyme responsible for breaking down cyclic GMP (cGMP).

As a result, cGMP accumulates, causing blood vessels to dilate. The researchers from the Weizmann Institute of Science in Israel tested sildenafil on both mouse and human cancer cells derived from various types of cancer. Their findings revealed that cGMP plays a dual role - it not only relaxes blood vessels but also binds to a protein that transports cholesterol within cells, a process crucial for building cell membranes.

These membranes prove beneficial for cancer cells when they attempt to spread to other parts of the body. Elevated cGMP activity, in turn, disrupts the supply of cholesterol, making cancer cells especially vulnerable. The study also analyzed health records of over 40,000 male cancer patients aged 35 to 65 who had previously taken sildenafil.

The results showed that these patients had a 26 percent higher survival rate five years after their cancer diagnosis. Moreover, when sildenafil was combined with statins, which reduce cholesterol production, the five-year survival rate increased to 32 percent. Study author Ayelet Erez explained that their research uncovered a new biological pathway linking a well-known signaling molecule to cholesterol regulation within cells, potentially allowing for interference with cancer cells' ability to form metastases.

Erez emphasized that their findings highlight the role of cancer biology being influenced not only by genetic mutations in tumor cells but also by the patient's metabolic state and existing medications. This discovery opens up possibilities for Viagra's therapeutic promise beyond its primary use and suggests that cancer biology may also be impacted by the patient's metabolic state and medications they are already taking.